Abstract
Submaximal dose pentagastrin tests conducted in normal male volunteers with L-643.441, a novel histamine H2-receptor antagonist, indicate that it is a potent and long-acting inhibitor of gastric acid secretion. The effect appears dose-dependent and single doses of 50 mg are sufficient to reduce secretory potential by at least 50% when examined 24 h after drug administration. No adverse effects attributable to treatment were observed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hobsley M., Silen W. Use of an inert marker (phenol red) to improve accuracy in gastric secretion studies. Gut. 1969 Oct;10(10):787–795. doi: 10.1136/gut.10.10.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petersen B., Christiansen J., Kirkegaard P., Olsen P. S. The stability of gastric acid secretion during prolonged pentagastrin stimulation in man. Clin Sci (Lond) 1984 Jan;66(1):99–101. doi: 10.1042/cs0660099. [DOI] [PubMed] [Google Scholar]
- Torchiana M. L., Pendleton R. G., Cook P. G., Hanson C. A., Clineschmidt B. V. Apparent irreversible H2-receptor blocking and prolonged gastric antisecretory activities of 3-N-(3-[3-(1-piperidinomethyl)phenoxy]propyl) amino-4-amino-1,2,5-thiadiazole-1-oxide (L-643, 441). J Pharmacol Exp Ther. 1983 Mar;224(3):514–519. [PubMed] [Google Scholar]